Abstract: A non-transitory computer-readable recording medium stores an information processing program for causing a computer to execute processing including: every time a plurality of data to be managed in a data lineage indicating histories of the plurality of data are updated, storing an update date and time in association with updated data; in response to an input of a designated date and time or a designated period, based on the update date and time stored in association with each of the plurality of data, determining data updated within a predetermined period including the designated date and time or within the designated period as data of interest; and generating a partial data lineage that is a part of the data lineage and includes a display object corresponding to the data of interest.

Abstract: A non-transitory computer-readable recording medium stores an information processing program for causing a computer to execute processing including: every time a plurality of data to be managed in a data lineage indicating histories of the plurality of data are updated, storing an update date and time in association with updated data; in response to an input of a designated date and time or a designated period, based on the update date and time stored in association with each of the plurality of data, determining data updated within a predetermined period including the designated date and time or within the designated period as data of interest; and generating a partial data lineage that is a part of the data lineage and includes a display object corresponding to the data of interest.

Abstract: A method for promoting myelination of an axon comprising administering 4-[?-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid is disclosed.

Abstract: The MAG expression promoter of the present invention contains a compound of the formula (I) wherein each symbol is as defined in the specification, an optically active form thereof or a pharmaceutically acceptable salt thereof. As a compound of the formula (I), 4-[?-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid is exemplified. The MAG expression promoter of the present invention is useful as an agent for the prophylaxis and/or treatment of a disease of mammals inclusive of human, which mainly presents hypomyelination, further, dysmyelination or demyelination.

Abstract: The MAG expression promoter of the present invention contains a compound of the formula (I) wherein each symbol is as defined in the specification, an optically active form thereof or a pharmaceutically acceptable salt thereof. As a compound of the formula (1), 4-[?-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid is exemplified. The MAG expression promoter of the present invention is useful as an agent for the prophylaxis and/or treatment of a disease of mammals inclusive of humans, which mainly presents hypomyelination, further, dysmyelination or demyelination.

Abstract: The culture supernatant of COS cells expressing the PSEC56 gene was found to have a neurite extension effect. The main substance of the activity contained in this culture supernatant was revealed to be NGF. It was shown that PSEC56 can be utilized as a neurotrophic factor expression-inducing agent, and that the NGF induction system can be utilized for drug development against diseases of the nervous system.